Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
Piramal Pharma Limited released its FY2026 Annual Report, reporting revenue of ₹8,869 crore despite global economic disruptions. The company emphasized its focus on science-led innovation and a resilient global manufacturing footprint.
MUMBAI, India , July 7, 2026 /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects Piramal Pharma's continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in